AstraZeneca’s mammoth Alexion takeover probed for competition concerns

Coronavirus vaccine maker AstraZeneca’s 39 billion US dollars (£27.5 billion) megadeal to buy America drug company Alexion Pharmaceuticals is being probed by the UK competition watchdog (Lynne Cameron/PA)
Coronavirus vaccine maker AstraZeneca’s 39 billion US dollars (£27.5 billion) megadeal to buy America drug company Alexion Pharmaceuticals is being probed by the UK competition watchdog (Lynne Cameron/PA)